)
ASP Isotopes (ASPI) investor relations material
ASP Isotopes Emerging Growth Conference 97 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business strategy and technology
Four verticals span nuclear medicine, electronic gases, medical isotopes and nuclear energy; Quantum Leap Energy is expected to spin out and be separately listed on Nasdaq.
South African plants for carbon-14, silicon-28 and ytterbium-176 are built; silicon-28 is operational and progressing toward its first batch shipment.
ASP and laser-based quantum enrichment processes target isotope supply gaps; the speaker cited zero U.S. domestic production for the isotopes under consideration and Russia as a major supplier.
Noble Africa began liquid helium production; first commercial isotope shipments are targeted before year-end, with helium shipments planned for December and January.
Nuclear medicine and radiopharmacies
PET Labs supplies tens of thousands of nuclear medicine doses annually in South Africa; NuMed and East Coast Nuclear Pharmacy operate in the U.S.
Focus is on higher-value cancer-treatment isotopes, including ytterbium-176 feedstock for lutetium-177 used in Novartis’ PLUVICTO; estimated future global ytterbium and gadolinium market is $100m.
Global nuclear medicine market estimated at $33bn, radiopharmaceuticals at $13.5bn and commercial radiopharmacy at $6bn; market growth forecast at 8% from 2026 to 2031.
Plan to acquire and upgrade radiopharmacies with advanced production capabilities; target is about 10 locations in five years and 30 in 10 years.
Alpa Theranostics pipeline
Alpa’s VHH nanobody platform pairs diagnostic and therapeutic radioisotopes; first candidates are expected to enter patients later in 2026, with Phase I data expected in 2027.
Three assets are planned to enter clinical development within six to nine months; initial focus includes triple-negative breast cancer and osteosarcoma.
Phase I trials are planned in South Africa, with a first U.S. IND filing targeted for 2027; management said the South African path from concept to IND could take about two years.
- Revenue grew, but losses and Renergen debt risks remain substantial.ASPI
Q3 2026 - Proprietary enrichment tech, global expansion, and strong financials drive $300–$700M 2031 EBITDA target.ASPI
CMD 2026 - Commercial production of isotopes and helium begins, targeting global supply gaps and strong growth.ASPI
Emerging Growth Conference - Quarterly revenue grew to $5.1M, net loss narrowed, and Renergen acquisition expanded operations.ASPI
Q2 2026 - Vertically integrated isotope and helium producer targets global expansion and strong financial growth.ASPI
Canaccord Genuity's 46th Annual Growth Conference - Phase I helium shipments begin September, with major expansion and strong contracts driving growth.ASPI
Investor update - Advancing isotope enrichment for semiconductors, medicine, and energy with 2026 milestones.ASPI
Corporate presentation - Expanding isotope enrichment and supply to critical markets with strong growth targets.ASPI
Corporate presentation - Commercial production ramped up across three plants, with strong cash reserves and growth outlook.ASPI
Q4 2024
)
)
)
)
)
)
)
)